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INTRODUCTION
In human cells, 95% of the multi-exon genes yield alternatively spliced transcripts, which can give rise to proteins with different functions and cellular locations (Khan et al., 2012 , Ip et al., 2011 , Hnilicova and Stanek, 2011 . Pre-mRNA splicing occurs co-transcriptionally in mammalian cells (Sperling et al., 2008 , Wahl et al., 2009 , Kalsotra and Cooper, 2011 . The regulation of alternative splicing is quite complex and is influenced by transcription rates, histone post-translational modifications (PTMs) and a variety of splicing factors (Braunschweig et al., 2013 , Bentley, 2014 . The rate of elongation through a gene is not uniform and is influenced by histone PTMs , Zhou et al., 2014 . The types of histone PTMs located along a transcribed gene body are polarized.
H3K4me3 is typically found at the 5' end of the gene body, followed by H3K36me3 further down the gene. In this review, we will focus on the relationship between H3K4me3 location at the beginning of the transcribed gene body and pre-mRNA splicing.
Histone modifications and chromatin structure/function
Nuclear DNA is packaged into nucleosomes, the basic repeating structural units in chromatin. The nucleosome consists of a histone octamer, arranged as a (H3-H4) 2 tetramer and two H2A-H2B dimers, around which DNA is wrapped. The core histones (H2A, H2B, H3, H4) have a similar structure with a basic N terminal domain, a globular domain organized by the histone fold, and a C terminal tail.
D r a f t 4
The N terminal tails emanate from the nucleosome in all directions and interact with linker DNA, nearby nucleosomes or with other proteins. Core histones undergo a variety of reversible PTMs, including acetylation, methylation and phosphorylation (Maze et al., 2014) . Histone PTMs are key players in the epigenetic regulation of gene expression. Histone PTMs are added to specific sites on the core histones by a variety of enzymes ("writers") (e.g. lysine acetyltransferases, KATs; lysine methyltransferases, KMTs), and removed by specific enzymes ("erasers") (e.g. histone deacetylases, HDACs; lysine demethylases, KDMs) (Allis et al., 2007) . Some histone PTMs (active marks) are associated with transcribed chromatin regions, while others (repressive marks)
are present in silent regions. Histone acetylation, H3K4me3 and H3K36me3 are active gene marks, whereas H3K9me3 and H3K27me3 are repressive marks.
Histone PTMs function to alter chromatin structure and/or provide a "code" for recruitment or occlusion of nonhistone chromosomal proteins to chromatin.
These recruited proteins are referred to as "readers". Thus the nucleosome is more than a structural unit; it is also a signalling unit (Turner, 2014) .
Pre-mRNA splicing, nucleosomes and transcription
Most human genes have exons separated by introns. The introns are removed from the transcript to join the exons together by a process called splicing ( Figure 1 ) to produce a mature RNA that is translated to synthesize a protein (Sperling et al., 2008) . Pre-mRNA splicing is a regulated stepwise process catalyzed by a multicomponent machine (the spliceosome) consisting of D r a f t 5 RNA and protein, and this process occurs co-transcriptionally in mammalian cells (Sperling et al., 2008 , Wahl et al., 2009 , Kalsotra and Cooper, 2011 .
There is a functional connection between chromatin organization and premRNA splicing (Luco et al., 2010 , Khan et al., 2012 , Sims et al., 2007 , de Almeida and Carmo-Fonseca, 2014 . Nucleosomes are non-uniformly distributed along the body of transcribed genes as they are enriched on exons relative to introns and have preferential positioning at exon-intron and intron-exon boundaries (Chodavarapu et al., 2010 , Tilgner et al., 2009 . Further, most internal exons are short, about the length of nucleosomal DNA (Tilgner et al., 2009 , Schwartz et al., 2009 ).
H3K4me3 genomic location
Typically H3K4me3 is viewed as a mark of an active promoter. However, in mammalian cells the predominant H3K4me3 peak is located at the end of the first exon at the site of the 5' splice site (Bieberstein et al., 2012) (Figure 1 ). To reach this conclusion, the authors used H3K4me3 chromatin immunoprecipitation (ChIP) sequencing data from the human ENCODE project (EncodeProjectConsortium, 2012 , EncodeProjectConsortium, 2011 . Current evidence shows that the location of the H3K4me3 modified nucleosomes along a transcribed gene body depends on 1) the location of a CpG island (unmethylated state) and 2) pre-mRNA splicing , Bieberstein et al., 2012 ( Figure 1 ).
D r a f t
H3K4me3 is highly biased towards genes with CpG islands, which are usually located at the 5' end of the gene body (Pal et al., 2011 , Maunakea et al., 2010 , Barrera et al., 2008 (Figure 1 and 2). H3K4me3 is not present at methylated CpG islands (Deaton et al., 2011) . Artificial CpG clusters introduced into the mouse genome at sites that normally lack H3K4me3 became associated with peaks of H3K4me3 modified nucleosomes in the absence of a promoter or any associated RNA polymerase (Thomson et al., 2010) . This result presents evidence that transcription is not a prerequisite for the establishment of H3K4me3. Although H3K4me3 locates preferentially to CpG islands, genes lacking CpG islands in their 5' region may also form peaks of H3K4me3 (Barrera et al., 2008) . Figure 3 shows the APOL1, APOL2 and TFF3 genes, which appear to lack CpG islands, have an H3K4me3 peak located at the end of the first exon in HepG2 cells. Note that for the APOL2 gene the H3K4me3 peak is located at the end of the first exon in HepG2, A549 and HCT116 cells.
As shown in Figures 2 and 3 , H3K4me3 is often located in several peaks.
The major peak(s) is located downstream to the transcription start site (TSS), while a lesser peak is upstream to the TSS aligning with the upstream promoter region of the gene (Barrera et al., 2008 , Barski et al., 2007 , Guenther et al., 2007 , Rahl et al., 2010 , Bieberstein et al., 2012 . H3K4me3 modified nucleosomes are often located at the first 5' splice site of transcribed mammalian genes, with the location of the H3K4me3 being dependent on pre-mRNA splicing (Bieberstein et al., 2012) . Inhibition of premRNA splicing resulted in the loss of the H3K4me3 located at the exon 1 5' splice site (Bieberstein et al., 2012) . Collectively, these reports suggest that the
CpG island location and splicing play roles in deciding which nucleosome(s) will be trimethylated at H3K4. However, neither are absolute requirements to form H3K4me3 sites as peaks of H3K4me3 can be formed in the absence of CpG islands and/or transcription (Barrera et al., 2008 , Thomson et al., 2010 .
H3K4me3 writers
Enzymes catalyzing H3K4 methylation include the MLL1, MLL2, MLL3, MLL4, SETD1A and SETD1B. The MLLs (1-4) catalyze mono-and di-methylation of H3K4 (Shilatifard, 2012 , Shinsky et al., 2015 . MLL1 has weak H3K4 trimethylation activity, which is stimulated in the presence of ubiquitinated H2B (Wu et al., 2013 , Binda, 2013 , Denissov et al., 2014 , Cao et al., 2014a . SETD1A
and SETD1B are responsible for most of the H3K4 trimethylation in human cells (van Nuland et al., 2013 , Shinsky et al., 2015 , Shilatifard, 2012 .
The SETD1A and SETD1B complexes consist of SET1A or 1B, ASH2L, WDR5, RBBP5, WDR82, DPY30 and CXXC1 ( Figure 1 ). The SETD1B complex has BOD1L, which is not present in the SETD1A complex (van Nuland et al., 2013) . The prominent activity in colorectal cancer HCT116 cells is SETD1A (Salz et al., 2014b) . In MDA-MB-231 triple negative breast cancer cells, both SETD1A
and 1B contribute to the genesis of H3K4me3 (Salz et al., 2014a) . Knocking down SETD1A reduced the cell growth and metastatic properties of colorectal cancer cells, and had a major impact on attenuating the expression of Wnt/β-catenin genes (Salz et al., 2014b) . Reducing SETD1A expression also lowered the metastatic properties of triple negative breast cancer cells, MDA-MB-231 and D r a f t BT549, and attenuated the expression of matrix metalloproteinases (Salz et al., 2014a) .
The recruiters of the H3K4 writers
Several players (CXXC1, uH2B, H3R2me2s) are involved in directing SETD1A/B to trimethylate H3K4 at specific sites in the 5' region of the gene body.
However, we lack an appreciation of the relative role of these recruiters.
CXXC1 (a.k.a. CFP1) binds to un-methylated CpG islands. Cxxc1 knockout murine embryonic stem cells are viable, but have several defects (e.g.
inability to differentiate in vitro) (Tate et al., 2010) . Disruption of mouse Cxxc1 results in embryonic lethality. The knockout embryonic stem cells had lower SETD1A activity, and importantly both SETD1A and H3K4me3 were mislocalized.
Similar results were obtained in CXXC1 knockdown NIH 3T3 cells (Thomson et al., 2010) . These authors reported that H3K4me3 at CpG islands was greatly reduced when CXXC1 was knocked down. Expression of full length Cxxc1 was required to restrict SETD1A and H3K4me3 to euchromatin in mammalian cells (Tate et al., 2010) . The CXXC1 subunit of SETD1A/B binds to the CpG island only when it is not methylated (Xu et al., 2011) .
Ubiquitinated H2B (uH2B) and H3 symmetrically dimethylated at R2 (H3R2me2s) are involved in the recruitment of the SETD1A/B complexes. We were the first to show that ubiquitination of H2B was dependent upon on-going transcription Murphy, 1990, Nickel et al., 1989) . RNF20-mediated ubiquitination of H2B was thought to be a prerequisite for trimethylation of H3K4 D r a f t (Shilatifard, 2012 , Ma et al., 2011 . However, uH2B had no direct regulatory role on Drosophila SET1 (Ardehali et al., 2011) . Furthermore, loss of Drosophila Ataxin-7, a subunit of the KAT SAGA, reduced levels of uH2B but there were no changes in H3K4me3 levels (Mohan et al., 2014) . Also, RNF20 knockdown in myoblasts resulted in a modest decrease in H3K4me3. The impact of uH2B loss on H3K4me3 at various loci was gene specific (Vethantham et al., 2012) . Thus, H2B ubiquitination is not always a prerequisite for H3K4 trimethylation (Wijeweera et al., 2015) .
In the mammalian genome, H3R2me2s, an active mark, colocalizes with
H3K4me3 (Jahan and Davie, 2014) . The PRMT catalyzing H3R2me2s is thought to be PRMT5 (a type II PRMT); however, this is not "locked down" at this time.
Knockdown of this enzyme did not alter H3R2me2s levels in Rag2 -/-Abelsontransformed pro-B cells (Yuan et al., 2012) . In contrast, PRMT5 knockdown in mouse primary hepatocytes did reduce H3R2me2s at specific gene loci (about 33%) (Tsai et al., 2013) . In HeLa cells, knockdown of PRMT5 and PRMT7 was effective in lowering H3R2me2s and H3K4me3 (Migliori et al., 2012) . WDR5, a component of the SETD1A/1B complexes, binds to H3R2me2s, providing a mechanism by which H3R2me2s recruits SETD1A/B (Binda, 2013) .
PRMT5 is also involved in pre-mRNA splicing (Bezzi et al., 2013) . As inhibition of splicing reduces H3K4me3 at the 5' splice site of the first exon (Bieberstein et al., 2012) , the role of PRMT5 in splicing rather than forming H3R2me2s may be responsible for reduction in H3K4me3 observed in PRMT5 knockdown cells (Migliori et al., 2012) .
H3K4me3 erasers
There are at least four enzymes that demethylate H3K4me3, which are in the KDM5 family (5A/JARID1A/RBP2, 5B/JARID1B/PLU1, 5C/JARID1C/SMCX and 5D/JARID1D/SMCY). The expression of the KDM5 enzymes is often deregulated in cancer cells (Van Rechem and Whetstine, 2014, Blair et al., 2011) .
KDM5A, a DNA-binding protein, has a role in breast cancer progression and metastasis; however, this activity of KDM5A may be independent of the protein's demethylase activity (Tu et al., 2008 , Cao et al., 2014b . The expression level of KDM5A correlated with the increased metastatic potential of the breast cancer cell (Cao et al., 2014b) . KDM5B is up-regulated in prostate and breast cancer (Xiang et al., 2007) . KDM5B is expressed at greater levels in breast cancer cells.
Further, estrogen receptor positive breast cancer cells (e.g. MCF7) express greater levels of KDM5B than do triple negative (MDA-MB-231) cells (Klein et al., 2014) . KDM5B knockdown in MDA-MB-231 cells resulted in global increases in H3K4me3 (Klein et al., 2014) , while in MCF7 cells, KDM5B knockdown did not alter global H3K4me3 levels but did reduce H3K4me3 at specific genes (Li et al., 2011 , Yamane et al., 2007 . Over-expression of KDM5B in MDA-MB-231 cells suppressed the metastatic properties of these cells (Klein et al., 2014) . However, knockdown of KDM5B reduces the growth of MCF7 cells (Barrett et al., 2007) .
Active and poised enhancers are marked by H3K4me1, while promoters and 5' regions of transcribed genes have H3K4me3. KDM5C is recruited to both enhancers and promoters. At enhancers, KDM5C has a simulating action in D r a f t keeping the enhancer in a H3K4me1 state. However, at promoters KDM5C has the opposite impact in dampening transcription (Outchkourov et al., 2013) .
Several of the KDM5 family members are associated with transcription factors, providing a mechanism for the recruitment of these enzymes to regulatory regions of the genome. For example, KDM5B binds to the androgen receptor in prostate cancer cells (Xiang et al., 2007) . KDM5B acts as a corepressor when recruited by MYC to specific regulatory regions (Wong et al., 2012) . In contrast to the recruitment of KDM5 family members to regulatory regions, the mechanism(s) by which the KDM5 enzymes are recruited to the gene body is not known. However, it is an interesting observation that all of the KDM5 family members are associated with HDAC1/2 (Li et al., 2011 , Barrett et al., 2007 , Tahiliani et al., 2007 . KDM5B is associated with the HDAC1/2 NuRD complex (Klein et al., 2014 , Li et al., 2011 . It is also possible that the KDM5 family members are associated with the HDAC1/2, which is bound to RNA splicing factors (such as SRSF1 and SF3B1-4) . In an analysis of the HDAC1/2 complexes in mammalian cells, we observed that the unphosphorylated HDAC1/2 were associated with the pre-spliceosome E/A complex (Figure 1) . Possibly one or more of the KDM5 family members are recruited to the HDAC1/2 -pre-spliceosome complex and positioned to catalyze the removal of the H3K4me3 mark. Further, the KDM5 family members undergo numerous PTMs including acetylation, ubiquitination and phosphorylation (Hornbeck et al., 2015) , and these (Lu et al., 2015) . The authors of this study suggest that a combinatory approach of inhibiting SKP2 and KDM5B may be an effective therapy in treating castration resistant prostate cancer (Lu et al., 2015) .
H3K4me3 dynamics
Once established, H3K4me3 is a relatively stable mark in interphase and mitotic cells. The H3K4me3 mark remains associated with mitotic chromosomes acting presumably as a mitotic bookmark for expression of specific genes in the daughter cell (Terrenoire et al., 2010 , Delcuve et al., 2009 , Zaidi et al., 2014 , Zaidi et al., 2011 . However, in interphase cells the H3K4me3 mark will increase and decrease with transcription induction and cessation, respectively, of inducible genes (Edmunds et al., 2008) . Primary response genes (e.g. levels to go back to basal levels (Ng et al., 2003) . Thus demethylation of H3K4me3 appears to be a slow process.
H3K4me3 readers
H3K4me3 has several readers including CHD1, FACT, the PAF complex, U2 snRNP and U2AF65, SAGA-associated factor 29, and the ING proteins (Guerillon et al., 2013 , Buratowski and Kim, 2010 , Shi et al., 2006 , Schram et al., 2013 , Sims et al., 2007 (Figure 1 ). CHD1 is an ATP-dependent chromatin remodeler, which binds to the SF3A subunit of the U2 snRNP complex. ING3, ING4/5 and ING5 are associated with the MYST family of KATs, including Tip60, HBO1 and MOZ/MORF (Lalonde et al., 2013) . FACT, consisting of Spt16 and SSRP1, has a role in the removal and the re-depositing of the H2A-H2B dimer during the passage of RNA polymerase II . The PAF D r a f t complex has a role in transcriptional elongation. The PAF complex is required by RNF20 to ubiquitinate H2B . The U2 snRNP complex recognizes the 3' splice site in an early step in splicing (Figure 1 ). The U2 snRNP has SF3A1-A3 and SF3B1-B5. U2AF65 is a U2 snRNP auxiliary factor that is an essential component of the pre-mRNA splicing machinery (Prigge et al., 2009 ). 
Clearly H3K4me3 is a nexus for proteins involved in transcriptional elongation

RNA and epigenetic modifiers
Nuclear RNA, coding or non-coding (ncRNA), regulates the structure and function of chromatin (Gardini and Shiekhattar, 2015, Guil and , Sjolinder et al., 2005 , Tyagi et al., 2009 , Khan et al., 2012 , Maxwell et al., 2013 , Tsai et al., 2010 , Gardini and Shiekhattar, 2015 . SETD1B binds to the MPL transcript (Xiao et al., 2014) . Thus, there is evidence that the enzymes catalyzing H3K4 trimethylation are associated with RNA. The association of these chromatin modifiers with RNA is often indirect, with the factor being recruited to RNA by RNA-binding proteins. For example, KAT2B is recruited to RNA by hnRNP U (Obrdlik et al., 2008) . Several of the epigenetic modifiers associating with RNA binding proteins have roles in pre-mRNA splicing (e.g. KAT2B, HDAC1/2, MeCP2) (Khan et al., 2012 , Liyanage et al., 2014 (Figure 1 ).
We recently reported that HDAC1 and HDAC2 were recruited to the gene body of a transcribed gene, with the recruitment of the HDACs being transcription-dependent . However, the HDAC1 and 2 were not associated with the chromatin but with the transcript. Using a dual crosslinking ChIP assay, HDAC1 and 2 appeared to be bound to the gene body of the transcribed gene. Yet, when the fragmented chromatin was digested with RNase A before adding the anti-HDAC1 or 2 antibodies, the association of the HDACs with the transcribed gene body was lost. These studies highlighted a caution in interpreting ChIP assay data. RNA-binding proteins involved in pre-mRNA splicing will be cross-linked to DNA with formaldehyde and will appear to be associated with the coding region of transcribed genes (Sapra et al., 2009 ).
D r a f t
However, addition of an RNase digestion step before doing the immunoprecipitation will demonstrate whether the RNA-binding protein is bound to RNA and not to chromatin. To demonstrate that HDAC1/2 and KAT2B were bound to the MCL1 transcript, we used a dual cross-linking CLIP protocol . As KDM5 family members are associated with HDAC1/2, it is possible that the KDM5 enzymes are also associated with RNA. Experimental approaches such as those described above will be required to determine whether this idea is correct.
H3K4me3 and pre-mRNA splicing efficiency
Reducing H3K4me3 
Dynamic histone acetylation, H3K4me3 and alternative pre-mRNA splicing
Nucleosomes with H3K4me3 are selectively dynamically acetylated (Wang et al., 2009 , Hendzel and Davie, 1991 , Hazzalin and Mahadevan, 2005 . mRNA. These events result in exon 2 exclusion . This study demonstrates how the strategic H3K4me3 modification of a nucleosome in a gene body confers to this nucleosome unique properties enabling a response to environmental changes. Thus in the context of a signaling module, the H3K4me3 modified nucleosome is quite different from its neighboring nucleosomes.
Disease and H3K4me3 nexus
Proteins/enzymes that regulate the level and location of H3K4me3 are deregulated in breast cancer. Further H3K4me3-binding proteins (readers) with roles in chromatin modification, elongation and RNA splicing are mutated in breast cancer. According to the Cancer Genome Atlas, KDM5B is frequently over-expressed in invasive ductal carcinoma cancer (Lu et al., 1999 , Cancer Genome Atlas, 2012 , Rasmussen and Staller, 2014 , Blair et al., 2011 . KDM5C is frequently mutated in X-linked mental retardation (Tzschach et al., 2006 , Blair et al., 2011 , Jensen et al., 2010 . KDM5C is also mutated in clear cell renal cell carcinomas (Blair et al., 2011) . ING1, 2 & 4 genes are often deleted in breast cancer (Guerillon et al., 2013) . The ING proteins are components of several epigenetic modifiers and readers of the H3K4me3 mark. SF3B1 and U2AF1
genes are often mutated in disease states (Scott and Rebel, 2013) . SF3B1 and SF3B3 genes are mutated in breast cancer (Scott and Rebel, 2013 , Cancer Genome Atlas, 2012 , Maguire et al., 2015 . SF3B1 and SF3B3 are part of the The genes coding for the MLL enzymes are often mutated in disease states. Mutations in MLL2 and MLL3 are found in the Kabuki 1 and Kleefstra syndromes, respectively (Parkel et al., 2013) . Further cancer mutations in MLL3 result in an enzyme catalyzing H3K4me3, which is in contrast to the wild type enzyme that produces H3K4me1 (Weirich et al., 2015) . Fusion proteins (MLL-AF9, MLL-ENL) produced by translocation events in cancer cells, result in mistargeting of the H3K4 methyltransferase activity of the MLL enzyme (Yokoyama, 2015, Li and Ernst, 2014) .
There are many examples of how cancer mutations in epigenetic modifiers such as EZH2 alter enzymatic activity. Recently, Weirich et al reported that the mutation Y4848S in MLL3 converts MLL3 from a H3K4 monomethyltransferase to a trimethyltransferase, resulting in increased levels of H3K4me3 in cancer cells (Weirich et al., 2015) . As MLL3/4 monomethylate H3K4 at enhancers (Hu et al., 2013) , such a mutation in MLL3 may alter the activity of enhancers (Weirich et al., 2015) .
Inhibitors of KDM5
Towards understanding the biological role of KDM5 family members and importantly in the treatment of cancers over-expressing KDM5 family members, several KDM5 inhibitors have been synthesized (Sayegh et al., 2013 , Thinnes et al., 2014 . Inhibitors of KDM5B include 2-4(4-methylphenyl)-1,2-benzisothiazol-D r a f t 21 3(2H)-one (PBIT), which inhibits KDM5B with an IC 50 of 3 µM in vitro (Sayegh et al., 2013) . KDM5A and KDM5C but not KDM6A or KDM6B are inhibited by PBIT (Thinnes et al., 2014) . PBIT is derived from a commonly used microbicide and fungicide, benzisothiazolinone, used in home cleaning products (Sayegh et al., 2013 
Inhibitors of pre-mRNA splicing and impact on H3K4me3
There are several inhibitors of pre-mRNA splicing. FR901464, meayamycin A/B and spliceostatin A bind to the splicing factor 3b complex (specifically SF3B1) and inhibit pre-mRNA splicing (Albert et al., 2009 , Gao and Koide, 2013 , Bieberstein et al., 2012 , Kaida et al., 2007 . Meayamycin A is a potent inhibitor of cancer cell (e.g. MCF7, MDA-MB-231, HCT116) proliferation (Albert et al., 2009) . The alternative splicing of MCL1 and BCL2L1 (also known as BCL-XL) is regulated by SRSF1 and SF3B1 (Moore et al., 2010) . Interestingly HDAC1 and 2 interact with both of these splicing factors .
Treatment of cancer cells (H1299, A549) with meayamycin B results in an increase in the production of MCL1S, the transcript lacking exon 2 and coding for an pro-apoptotic protein (Gao and Koide, 2013 
Concluding remarks
H3K4me3 is one of the most studied marks used in identifying promoter regions in epigenome mapping studies (Roadmap Epigenomics et al., 2015) .
Although often stated as a mark of active/poised promoters, the major H3K4me3 (Braunschweig et al., 2013) . The definition of a CpG island is a region with at least 200 bp and GC percentage that is greater than 50%, and with an observed to expected CpG ratio that is greater than 60%.
M, methylation; Ac, acetylation. 
